Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.57 |
| ▸ | ARG2 | P78540 | 5/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958570 | 1.00 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL259006 | 0.98 | GSR (0.59) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL17262412 | 0.98 | GSR (0.59) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL3423971 | 0.98 | GSR (0.59) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL79859 | 0.91 | GSR (0.56) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL198242 | 0.91 | GSR (0.56) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL2722969 | 0.91 | GSR (0.56) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL30463729 | 0.89 | GSR (0.54) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29624332 | 0.87 | GSR (0.44) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL4956653 | 0.86 | GSR (0.74) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| EP-4539887-A1 | INTERLEUKIN-2 PRODRUGS | Merck Sharp & Dohme LLC (US) | 2025-04-23 | — | — | EP | claimed |
| US-20240287151-A1 | IL-15 Conjugates and Uses Thereof | Synthorx, Inc. (US) | 2024-08-29 | — | — | US | claimed |
| US-20240101631-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | claimed |
| US-11919934-B2 | IL-15 conjugates and uses thereof | Synthorx, Inc. (US) | 2024-03-05 | — | — | US | claimed |
| WO-2023244517-A1 | INTERLEUKIN-2 PRODRUGS | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | claimed |
| EP-4139340-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | Merck Sharp & Dohme LLC (US) | 2023-03-01 | — | — | EP | claimed |
| EP-4041247-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | claimed |
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220243244-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2022-08-04 | — | — | US | claimed |
| US-20200231644-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SANOFI (FR) | 2020-07-23 | — | — | US | claimed |
| US-20200188484-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2020-06-18 | — | — | US | claimed |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SYNTHORX INC (US) | 2020-06-11 | — | — | US | claimed |
| EP-3661955-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3661956-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| CN-111194322-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2020-05-22 | — | — | CN | claimed |
| CN-111183149-A | Cytokine conjugates for the treatment of autoimmune diseases | 辛索克斯公司 | 2020-05-19 | — | — | CN | claimed |
| WO-2019165453-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2019-08-29 | — | — | WO | claimed |
| WO-2019028419-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | claimed |
| WO-2019028425-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188484-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | GSR 1429/4885ARG2 227/4885ARG1 640/4885 |
| US-20240287151-A1 | IL-15 Conjugates and Uses Thereof | IL15, IL15RA, IL2 | GSR 2558/4885ARG2 1273/4885ARG1 655/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | GSR 782/4885ARG2 267/4885ARG1 828/4885 |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | GSR 1429/4885ARG2 227/4885ARG1 640/4885 |
| US-20240101631-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | IL2, IL2RA, IL6ST | GSR 3662/4885ARG2 543/4885ARG1 1227/4885 |
| US-20200231644-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | GSR 782/4885ARG2 267/4885ARG1 828/4885 |
| US-11919934-B2 | IL-15 conjugates and uses thereof | IL15, IL15RA, IL2 | GSR 2558/4885ARG2 1273/4885ARG1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.